We are live on ! Find out more

1,742 hedge funds and large institutions have $133B invested in Pfizer in 2014 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 750 increasing their positions, 716 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more call options, than puts

Call options by funds: $1.91B | Put options by funds: $1.38B

15% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 60

5% more repeat investments, than reductions

Existing positions increased: 750 | Existing positions reduced: 716

0% less funds holding

Funds holding: 1,7461,742 (-4)

0% less capital invested

Capital invested by funds: $133B → $133B (-$559M)

0.91% less ownership

Funds ownership: 73.97%73.06% (-0.91%)

3% less funds holding in top 10

Funds holding in top 10: 198193 (-5)

Holders
1,742
Holders Change
-4
Holders Change %
-0.23%
% of All Funds
50.54%
Holding in Top 10
193
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-2.53%
% of All Funds
5.6%
New
69
Increased
750
Reduced
716
Closed
60
Calls
$1.91B
Puts
$1.38B
Net Calls
+$533M
Net Calls Change
-$162M
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$1.28B +$41.1M +1,464,217 +3%
Fidelity Investments
27
Fidelity Investments
Massachusetts
$1.19B -$64.9M -2,310,804 -5%
Goldman Sachs
28
Goldman Sachs
New York
$1.17B +$106M +3,780,805 +10%
LSV Asset Management
29
LSV Asset Management
Illinois
$1.1B +$90.4M +3,222,693 +9%
Boston Partners
30
Boston Partners
Massachusetts
$1.07B +$45.1M +1,607,379 +4%
Morgan Stanley
31
Morgan Stanley
New York
$1.02B -$287K -10,224 -0%
IC
32
Institutional Capital
Illinois
$962M -$185M -6,600,827 -16%
TCIM
33
TIAA CREF Investment Management
New York
$945M -$61M -2,174,918 -6%
Fisher Asset Management
34
Fisher Asset Management
Washington
$937M +$6.51M +231,887 +0.7%
Legal & General Group
35
Legal & General Group
United Kingdom
$868M -$57.2M -2,037,875 -6%
Neuberger Berman Group
36
Neuberger Berman Group
New York
$837M -$69.8M -2,485,742 -8%
BIM
37
BlackRock Investment Management
Delaware
$768M -$35.5M -1,265,626 -4%
MAA
38
Managed Account Advisors
New Jersey
$764M -$26.2M -932,325 -3%
Charles Schwab
39
Charles Schwab
California
$752M +$44.6M +1,588,738 +6%
UBS AM
40
UBS AM
Illinois
$725M +$13.6M +484,313 +2%
Wells Fargo
41
Wells Fargo
California
$698M +$9.21M +328,196 +1%
PNC Financial Services Group
42
PNC Financial Services Group
Pennsylvania
$664M +$88.1M +3,137,292 +15%
Allianz Asset Management
43
Allianz Asset Management
Germany
$658M +$80.1M +2,854,700 +14%
Lazard Asset Management
44
Lazard Asset Management
New York
$643M -$179M -6,387,518 -22%
American Century Companies
45
American Century Companies
Missouri
$642M -$5.85M -208,531 -0.9%
CS
46
Credit Suisse
Switzerland
$637M +$62.5M +2,226,353 +11%
LP
47
Longview Partners
Guernsey
$618M -$6.69M -238,408 -1%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$613M -$3.35M -119,495 -0.5%
Nordea Investment Management
49
Nordea Investment Management
Sweden
$596M +$15.9M +565,145 +3%
BlackRock
50
BlackRock
New York
$590M -$41.4M -1,476,789 -7%

PFE Hedge Fund Activity: Q3 2014 in Review

1,742 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2014, worth a combined $133B — down 0.42% from $133B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new PFE positions and 60 closed out — a net gain of 9 holders — while 750 added to existing stakes and 716 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $258M. The largest seller was Norges Bank, cutting an estimated $1.53B.

  • 1,742 institutional investors held Pfizer (PFE) as of Q3 2014, down from 1,746 in Q2 2014.
  • Funds reported $133B of Pfizer stock for Q3 2014, down 0.42% quarter-over-quarter.
  • 69 funds opened new Pfizer positions in Q3 2014 and 60 closed out, a net change of +9 holders.
  • The largest Pfizer buyer in Q3 2014 was D.E. Shaw & Co, an estimated $258M added.
  • The largest Pfizer seller in Q3 2014 was Norges Bank, an estimated $1.53B sold.

Based on aggregated 13F filings for Q3 2014.